Bingliang Fang

8PUBLICATIONS
77CO-AUTHORS
Molecular targetsHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cardiology (incl. cardiovascular diseases)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Feb 13, 2025
Modulation of tumor inflammatory signaling and drug sensitivity by CMTM4.

Yitian Xu, Kyeongah Kang, Brian A Coakley

|Jul 31, 2024
A Pan-Cancer Patient-Derived Xenograft Histology Image Repository with Genomic and Pathologic Annotations Enables Deep Learning Analysis.

Brian S White, Xing Yi Woo, Soner Koc

|Sep 14, 2022
WNT5A-RHOA Signaling Is a Driver of Tumorigenesis and Represents a Therapeutically Actionable Vulnerability in Small Cell Lung Cancer.

Kee-Beom Kim, Dong-Wook Kim, Youngchul Kim

|Dec 03, 2021
Epstein Barr virus-positive B-cell lymphoma is highly vulnerable to MDM2 inhibitors in vivo.

Xiaoshan Zhang, Ran Zhang, Chenghui Ren

|Dec 05, 2020
A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers.

Masanori Kawakami, Lisa Maria Mustachio, Yulong Chen

|Jul 15, 2020
The laboratory's role in combating COVID-19.

Bingliang Fang, Qing H Meng

Pageof 2

Frequent Collaborators

2 joint publications

Qing H Meng

1 joint publications

Apar Pataer

1 joint publications

Jason Roszik

1 joint publications

Jonathan M Kurie